Literature DB >> 1866149

Triple agent immunosuppression in serpiginous choroiditis.

P L Hooper1, H J Kaplan.   

Abstract

Serpiginous choroidopathy is a progressive choroidal inflammatory disorder that typically has a variable saltatory course. Response to steroids is uncertain. By using azathioprine, cyclosporine, and prednisone in combination, the authors have observed rapid remission of active disease in five patients. Remissions have been maintained for periods up to 18 months. Because of the synergistic effects of this combination, doses could rapidly be reduced to maintenance levels without reactivation. Disease in two patients recurred immediately after discontinuation of low-dose therapy but was arrested when therapy resumed. Triple agent immunosuppressive therapy is well tolerated and appears to be effective.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1866149     DOI: 10.1016/s0161-6420(91)32198-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  27 in total

Review 1.  Immunosuppression in uveitis therapy.

Authors:  R N Van Gelder; H J Kaplan
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Ophthaproblem. Geographic choroidopathy.

Authors:  J Cheung; S Sharma
Journal:  Can Fam Physician       Date:  2000-10       Impact factor: 3.275

Review 3.  Advances in the diagnosis and immunotherapy for ocular inflammatory disease.

Authors:  Steven Yeh; Lisa J Faia; Robert B Nussenblatt
Journal:  Semin Immunopathol       Date:  2008-03-05       Impact factor: 9.623

Review 4.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

Review 5.  Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis.

Authors:  Hossein Nazari Khanamiri; Narsing A Rao
Journal:  Surv Ophthalmol       Date:  2013-03-27       Impact factor: 6.048

6.  [White dot syndromes : Principles, diagnostics, and treatment].

Authors:  Dominika Pohlmann; Sibylle Winterhalter; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2019-12       Impact factor: 1.059

Review 7.  Uveitis: contrasting the approaches in Japan and the United States.

Authors:  James T Rosenbaum
Journal:  Jpn J Ophthalmol       Date:  2018-11-20       Impact factor: 2.447

Review 8.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

9.  Azathioprine for ocular inflammatory diseases.

Authors:  Sirichai Pasadhika; John H Kempen; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; James T Rosenbaum; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; Eric B Suhler
Journal:  Am J Ophthalmol       Date:  2009-07-01       Impact factor: 5.258

Review 10.  [White dot syndrome].

Authors:  W Göbel
Journal:  Ophthalmologe       Date:  2008-01       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.